Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Paradigm Biopharmaceuticals (PAR) taps investors for $66 million to fund developments into the 2024 calendar year The fully underwritten capital raise will comprise a $45.7 million institutional placement and a $20.3 million entitlement of...

Recent cap raising suggests biotechs may finally be making a comeback Mesblast annnounced a US$45m cap raise last week Today, Paradigm, Opthea, and Proteomics also announced fund raises Over the past year, the biotech sector has been caug...

The GPT Group (ASX: GPT) share price is making a commendable move upwards today following the release of its interim results for 2022. At the time of writing, shares in the diversified property group are 5.7% in the green. As a result, th...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. I have been entrusted...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is plummeting after coming out of a trading halt this morning. At the time of writing, the biopharmaceutical company’s shares are fetching at $1.45, down 26.95%. What’s drivi...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. When the market is do...

ASX 200 and small caps rise circa 1% Regional markets jump on strong leads, US inflation data Ragusa Metals: up 60% Local markets took off at the open, feeling a little of the excitement which took hold of Wall Street overnight. The bench...

Paradigm Biopharmaceuticals (PAR) enters into a trading halt ahead of a capital raise There is currently no details on how much the company is aiming to raise or where it plans to spend the money Under the halt, company shares will be paus...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is going nowhere today after the company requested a trading halt.  The Paradigm share price has rocketed from $1.05 per share on 28 July to $1.99 per share at Wednesday’s close...

Listed drug repurposing business Paradigm Biopharmaceuticals has put a big raise to investors, asking them to tip in $62 million while it waits for key trial results.

The Nickel Industries Ltd (ASX: NIC) share price closed lower on Monday amid a significant debt announcement by the mineral exploration company. Nickel Industries shares finished the day down 1.82% at $1.08 each after hitting an intraday l...

Drug developer Paradigm Biopharmaceuticals [ASX:PAR] rose more than 10% on Monday after releasing an update on its clinical program. The post Paradigm [ASX:PAR] Spikes on Clinical Program Update appeared first on Money Morning Australia.

It’s been a slow start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. As it stands today, the ASX 200 has risen by an anaemic 0.07% and is hovering around the 7,020 point mark. So let’s dig a little deeper into t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up slightly to 7,017.1 points. Four ASX shares that are climbing more than most today are listed...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Even with the curren...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Warren Buffett has a...

The Paradigm Biopharmaceuticals Limited (ASX: PAR) share price is soaring today amid news the company will present its research at an international conference. Paradigm shares are trading at $1.92 each, up 11.63%, at the time of writing. E...

Wesfarmers Ltd (ASX: WES) shares are among the most popular ASX blue chip investments on the S&P/ASX 200 Index (ASX: XJO) today. This ASX 200 industrial and retailing conglomerate is now the ninth-largest share on the ASX 200 index by...

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

The Mayne Pharma Group Ltd (ASX: MYX) share price is up 4.48% on Monday morning amid news the company has received US regulatory approval. Shares of Mayne Pharma are currently trading at 35 cents each after opening at 33.5 cents a share th...

The OZ Minerals Limited (ASX: OZL) share price has shot higher to be the best performer in the S&P/ASX 200 Index (ASX: XJO) at the time of writing. OZ Minerals shares are currently trading for $25.51 each, a 34.83% leap from their prev...

ShareCafeEvening Report: 13 July, 2022 by Melissa Darmawan   Australian shares lacked conviction as investors remained cautious ahead of the US inflation data. The index remained in a holding pattern as it jumped above and below the flat li...

Paradigm Biopharmaceuticals (PAR) enters into a corporate partnership with NFL Alumni Health The partnership will inform NFL Alumni members about osteoarthritis disease onset, current treatment options, and provide information about clinic...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is in the green on Wednesday following the company’s latest announcement. At the time of writing, the biopharmaceutical company’s shares are fetching at $1.055 each, up 0.48%...

ShareCafeLunch Report: 13 July, 2022 by Melissa Darmawan   Australian stocks have lacked conviction today, shuffling above and below the flat line as investors weigh up the prospect of an aggressive rate hiking path to combat multi-year hig...

ShareCafeEvening Report: 6 July, 2022 by Lauren Evans   Australian shares spent the afternoon in the red as commodity prices plunged on recession fears. The energy sector tumbled 5.8 per cent, with materials down 5 per cent. Real estate was...

ResApp gets clearance from the US FDA Immutep is granted patent in Japan Paradigm Biopharma to commence Phase 3 trial ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a prescription-only Software-as-a-M...

ShareCafeLunch Report: 6 July, 2022 by Melissa Darmawan   The Australian sharemarket has been choppy this morning, trading as low as 0.5 per cent before rebounding to a gain of 0.2 per cent to then fall again. Information technology shares...

Paradigm Biopharmaceuticals (PAR) activates its first trial site in the United Kingdom for a third-phase trial of its Zilosul treatment for knee osteoarthritis The news comes after the company received UK regulatory and ethics approvals to...

Paradigm Biopharmaceuticals’ (ASX:PAR) investment relations guy Simon White is a bit different to your average biotech corporate gun for hire, given he’s actually tried the remedy he is promoting. A footballer with the AFL’s Carlton Footbal...

Paradigm Biopharmaceuticals (PAR) completes recruitment for its phase two clinical trial for treating knee osteoarthritis (OA) The phase two study aims to evaluate the treatment of pentosan polysulphate sodium (PPS) against a placebo in 6...

Wall Street had its worst ever start to the year in 50 years New data suggests the US economy is losing steam The ASX 200 is set to open higher today Wall Street tumbled again overnight by 1%, ending June as its worst ever start to the ye...

ShareCafeEvening Report: 30 June, 2022 by Melissa Darmawan   The Australian sharemarket closed at session lows and had its worst day in two weeks in a broad-based rout. At the closing bell, the S&P/ASX 200 was almost 2 per cent or 132 p...

A number of ASX shares in the S&P/ASX 200 Health Care Index (ASX: XHJ) outperformed the broader market today. The benchmark S&P/ASX 200 Index (ASX: XJO) backtracked yet again, ending Thursday’s session 1.97% lower at 6,568.1 poin...

Paradigm Biopharmaceuticals (PAR) receives approval from IP Australia for a key patent application for its knee osteoarthritis treatment The patent is for the treatment of bone marrow pathologies with PAR’s pentosan polysulphate sodium (PP...

ShareCafeLunch Report: 30 June, 2022 by Melissa Darmawan   The Australian sharemarket has fallen for a second day and is on track to have its worst month since March 2020. At noon, the S&P/ASX 200 is 0.8 per cent or 52 points lower at 6...

30 Jun 2022 - A snapshot of the stocks on the move featuring, Paradigm Biopharmaceuticals (ASX:PAR), Estrella Resources (ASX:ESR), and Race Oncology (ASX:RAC).

Cann Group’s Mildura facility has been granted GMP licence Paradigm receives patent application acceptance by IP Australia Starpharma to relaunch VIRALZEE with LloydsPharmacy in the UK Cannabis company Cann Group (ASX:CAN) rose 17% this m...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price isn’t letting the market weakness hold it back today. In morning trade, the biopharmaceutical company’s shares are up 20% to $1.15. Why is the Paradigm share price surging high...

ASX is set to open slightly higher today Major central bank bosses spoke overnight Wall Street ended the day mixed  Overnight, Wall Street wobbled as the most powerful central bankers in the world delivered a grim prediction. Speaking at...

Paradigm Biopharmaceuticals (PAR) receives an $8.2 million research and development tax incentive refund The clinical stage biopharmaceutical company was granted the refund as part of Australia’s R&D tax incentive scheme Paradigm quali...

ShareCafeEvening Report: 30 May, 2022 by Lauren Evans   The ASX 200 rose for a second successive day led by technology, materials and bank shares. At the closing bell, the index was 1.5 per cent or 104 points higher at 7,287, its best perfo...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is heading north during early afternoon trade on Monday. This follows the company’s latest announcement regarding a key appointment to its senior management team. At the time of wr...

ShareCafeLunch Report: 30 May, 2022 by Melissa Darmawan   Australian shares jumped to a three week high after a strong lead from Wall St. Every sector is rallying, bar utilities after news from AGL. The optimism is led by technology shares,...

Paradigm Biopharmaceuticals (PAR) appoints experienced pharmaceutical industry executive Marco Polizzi as its new CEO, effective July 1 With over 30 years of experience in the field, Mr Polizzi has a proven track record highlighted by seve...

ASX to open higher after a rally on Wall Street on Friday Bubs Australia has scored a significant export deal with the Biden government Australia’s GDP data to be released on Wednesday A strong surge on Wall Street on Friday is driving fu...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is racing higher during early afternoon trade on Thursday. This comes after the biopharmaceutical company provided an update on its pivotal phase 3 clinical trial. At the time of w...

Paradigm Biopharmaceuticals (PAR) begins dosing subjects in phase 3 of its clinical trial to test its Zilosul treatment for knee osteoarthritis pain The aim of the study is to measure the change in pain and function when receiving the inje...

Paradigm Biopharmaceuticals (ASX:PAR), a clinical-stage biopharmaceutical company focused on repurposing existing molecules for new indications with unmet clinical needs, says the first subjects have been randomised and dosed in the...

With Tuesday trade in the casket, the ASX Emerging Companies (XEC) index has closed about 1% lower, while the ASX 200 (XJO) benchmark index is down 0.5%, Everywhere markets fell, but for Paris, which has breathed a rich, garlic-scented merd...